ClinicalTrials.govpublic full text
Primary Cardiovascular Risk Prevention With Aspirin in Chronic Kidney Disease Patients
chronic kidney disease stage 4, chronic kidney disease stage 3, cardiovascular events, chronic kidney disease, bleedings, progression, antiinflammatory effects, interventional, phase3
This document is indexed with metadata only — full text is not available in the archive for this record.
Open the official source ↗
Related documents
Record · ID 839066
Retrieved via
Conceptio — every document is proof-bundled with source, license, and retrieval metadata.